# Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial

**Authors:** Isabel Martín‐Fuentes, Beatriz Fernandez‐Gamez, Sol Vidal‐Almela, Alfredo Caro‐Rus, Patricio Solis‐Urra, Lucía Sánchez‐Aranda, Javier Fernández‐Ortega, Javier Sanchez‐Martinez, Andrea Coca‐Pulido, Marcos Olvera‐Rojas, Emilio J. Barranco‐Moreno, Jose D. Marin‐Alvarez, Esmée A. Bakker, Angel Toval, Darío Bellón, Alessandro Sclafani, Thomas K. Karikari, Kirk I. Erickson, Manuel Gómez‐Río, Francisco B. Ortega, Irene Esteban‐Cornejo

PMC · DOI: 10.1002/brb3.70636 · Brain and Behavior · 2025-10-31

## TL;DR

This study explores how different types of exercise affect brain blood flow and Alzheimer's biomarkers in older adults to help prevent the disease.

## Contribution

The study introduces a novel crossover trial examining acute exercise effects on cerebral blood flow and AD biomarkers in amyloid-negative older adults.

## Key findings

- Aerobic exercise is expected to have greater acute effects on cerebral blood flow compared to resistance exercise and rest.
- Blood biomarkers of AD pathology are expected to fluctuate dynamically following exercise.
- Multimodal assessments will provide insights into exercise's impact on neurovascular mechanisms related to Alzheimer's prevention.

## Abstract

Alzheimer's disease (AD) is a leading cause of disability worldwide. Alterations in cerebral blood flow (CBF) and AD blood biomarkers are fundamental at early stages of AD. Exercise shows promise in delaying physiological changes, but its mechanisms for enhancing brain health remain unclear. flADex aims to examine the acute effects of different exercise types on CBF and blood biomarkers in older adults. This protocol describes the methodology and rationale of flADex.

flADex is a counterbalanced crossover trial in 20 older adults, aged 68–83 years old, with negative brain amyloid status (< 12 centiloid) who are APOEε4 noncarriers. Participants will complete a 30‐min session of each condition in a randomized order: (i) moderate‐intensity aerobic exercise (60%–70% age‐predicted maximal heart rate), (ii) moderate‐intensity resistance exercise (rating of perceived exertion: 4–6 points out of 10), and (iii) resting condition. Changes in CBF are the primary outcome and will be assessed by magnetic resonance imaging using pseudo‐continuous arterial spin labeling at pre‐ and at 3 timepoints post‐condition (starting at 20, 27, 34 min). Secondary outcomes are biomarkers of AD pathology and neurodegeneration (Aβ42, Aβ40, p‐tau217, p‐tau181, BD‐tau, GFAP, NfL) and growth factors (BDNF, IGF‐1), measured through blood samples collected at pre‐ and post‐condition (at 3, 50, 70 min). Moreover, cognitive outcomes and mood status will be measured pre‐ and post‐condition.

flADex will highlight the acute effects of different exercise types on CBF and biomarkers before beta‐amyloid accumulation. Acute effects on CBF dynamics and blood biomarkers are expected to be greater with aerobic than resistance exercise when compared to resting. CBF is expected to vary by brain region, and biomarkers to fluctuate dynamically postexercise. This will provide critical insights into exercise's impact on vascular and molecular pathways associated with AD pathology and potential recommendations for standardized blood sampling to enhance diagnostic accuracy.

This randomized crossover trial investigates how acute aerobic and resistance exercise influence cerebral blood flow, Alzheimer's‐related blood biomarkers, cognition, and mood in older adults. Using multimodal assessments, the flADex study aims to uncover neurovascular mechanisms for Alzheimer's prevention.

## Linked entities

- **Proteins:** GFAP (glial fibrillary acidic protein), NEFL (neurofilament light chain), BDNF (brain derived neurotrophic factor), IGF1 (insulin like growth factor 1)
- **Diseases:** Alzheimer's disease (MONDO:0004975)

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** AD (MESH:D000544), beta-amyloid (MESH:C000718787), neurodegeneration (MESH:D019636), brain amyloid (MESH:D001927)
- **Chemicals:** flADex (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12577972/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12577972/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12577972/full.md

---
Source: https://tomesphere.com/paper/PMC12577972